The Copmparison of Accuracy of PtcCO2 and in PetCO2 in COPD Patients With NIV Treatment
1 other identifier
observational
10
1 country
1
Brief Summary
The chronic obstructive pulmonary disease (COPD) patients with type II respiratory failure always needs PaCO2 test to monitor the changes of disease. Method used mostly nowadays to detect PaCO2 is arterial puncture which is accurate but is invasive, painful and non-dynamic. Noninvasive measurement methods includes end-tidal CO2 (PetCO2), transcutaneous CO2 (PtcCO2) which can monitor the PaCO2 dynamically and noninvasively, but their accuracy is in controversy. Common PetCO2 is especially inaccurate in COPD patients while our team find that the accuracy can be improved by prolong expiration method (PetCO2 (P)).So the investigators want to compare the accuracy of PtcCO2 and PetCO2(P) in AECOPD patients during noninvasive ventilation(NIV).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 8, 2019
CompletedFirst Submitted
Initial submission to the registry
February 2, 2020
CompletedFirst Posted
Study publicly available on registry
February 6, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedFebruary 23, 2021
February 1, 2021
2.9 years
February 2, 2020
February 21, 2021
Conditions
Outcome Measures
Primary Outcomes (3)
partial arterial pressure of end-tidal CO2 measured by prolong expiration method [PetCO2(P)]
PetCO2(P) will be measured before and after NIV treatment.
2 hours
partial arterial pressure of transcutaneous CO2 (PtcCO2)
PtcCO2 will be measured before and after NIV treatment.
2 hours
partial arterial pressure of carbon dioxide (PaCO2)
PaCO2 will be measured before and after NIV treatment.
2 hours
Study Arms (1)
AECOPD group
The study incruit AECOPD patients with type II respiratory failure who need the NIV treatment.
Interventions
Eligibility Criteria
AECOPD patients with type II respiratory failure who need NIV treatment
You may qualify if:
- AECOPD patients with type II respiratory failure who need NIV treatment
You may not qualify if:
- hemodynamics is unstable;
- any other lung disease despite COPD;
- other diseases influencing experiments: Cognitive impairment disease mouth and nose trauma.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zhenfeng Helead
Study Sites (1)
The First Affiliated Hospital of Guangzhou Medical University.
Guangzhou, Guangdong, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
February 2, 2020
First Posted
February 6, 2020
Study Start
February 8, 2019
Primary Completion
December 31, 2021
Study Completion
December 31, 2021
Last Updated
February 23, 2021
Record last verified: 2021-02